Catalog No.: PC-38340Not For Human Use, Lab Use Only.
Avotaciclib (BEY1107) is a potent, selective CDK1 (Cyclin-Dependent Kinase 1) inhibitor, inhibits self-replication of cancer stem cells and is a candidate for pancreatic cancer treatment.
Avotaciclib (BEY1107) is a potent, selective CDK1 (Cyclin-Dependent Kinase 1) inhibitor, inhibits self-replication of cancer stem cells and is a candidate for pancreatic cancer treatment.
CDK1 is a cell cycle control protein involved in cell division process, blocks G2/M phase in cell division, and eliminates cancer stem cells.
BEY1107 not only controls the cell division of cancer cells but also may overcome the tolerance on anti-cancer drugs with targeting mechanism by eliminating cancer stem cells.
BEY1107 showed synergistic effects of inhibiting metastasis of cancer cell combined with gemcitabine for pancreatic cancer.
Physicochemical Properties
M.Wt
281.279
Formula
C13H11N7O
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
2,6-bis(2-aminopyrimidin-4-yl)pyridin-3-ol
References
1. Wang Q, et al. NPJ Precis Oncol. 2023 Jun 13;7(1):58.
